These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 16608378)

  • 1. A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease.
    Kirby J; Green C; Loveman E; Clegg A; Picot J; Takeda A; Payne E
    Drugs Aging; 2006; 23(3):227-40. PubMed ID: 16608378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
    Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
    Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.
    Pouryamout L; Dams J; Wasem J; Dodel R; Neumann A
    Drugs; 2012 Apr; 72(6):789-802. PubMed ID: 22480339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
    Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
    JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective.
    Jones RW; McCrone P; Guilhaume C
    Drugs Aging; 2004; 21(9):607-20. PubMed ID: 15260515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
    Wilcock GK; Ballard CG; Cooper JA; Loft H
    J Clin Psychiatry; 2008 Mar; 69(3):341-8. PubMed ID: 18294023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil.
    Weycker D; Taneja C; Edelsberg J; Erder MH; Schmitt FA; Setyawan J; Oster G
    Curr Med Res Opin; 2007 May; 23(5):1187-97. PubMed ID: 17519086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain.
    Antonanzas F; Rive B; Badenas JM; Gomez-Lus S; Guilhaume C
    Eur J Health Econ; 2006 Jun; 7(2):137-44. PubMed ID: 16670912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
    Jönsson L
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic.
    Riordan KC; Hoffman Snyder CR; Wellik KE; Caselli RJ; Wingerchuk DM; Demaerschalk BM
    Neurologist; 2011 Mar; 17(2):121-3. PubMed ID: 21364371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).
    Knapp M; King D; Romeo R; Adams J; Baldwin A; Ballard C; Banerjee S; Barber R; Bentham P; Brown RG; Burns A; Dening T; Findlay D; Holmes C; Johnson T; Jones R; Katona C; Lindesay J; Macharouthu A; McKeith I; McShane R; O'Brien JT; Phillips PPJ; Sheehan B; Howard R
    Int J Geriatr Psychiatry; 2017 Dec; 32(12):1205-1216. PubMed ID: 27739182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation.
    Hartz S; Getsios D; Tao S; Blume S; Maclaine G
    BMC Neurol; 2012 Feb; 12():2. PubMed ID: 22316501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memantine for dementia.
    Areosa SA; Sherriff F
    Cochrane Database Syst Rev; 2003; (3):CD003154. PubMed ID: 12917950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil.
    van Dyck CH; Schmitt FA; Olin JT;
    Am J Geriatr Psychiatry; 2006 May; 14(5):428-37. PubMed ID: 16670247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials.
    Winblad B; Jones RW; Wirth Y; Stöffler A; Möbius HJ
    Dement Geriatr Cogn Disord; 2007; 24(1):20-7. PubMed ID: 17496417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis.
    Tricco AC; Ashoor HM; Soobiah C; Rios P; Veroniki AA; Hamid JS; Ivory JD; Khan PA; Yazdi F; Ghassemi M; Blondal E; Ho JM; Ng CH; Hemmelgarn B; Majumdar SR; Perrier L; Straus SE
    J Am Geriatr Soc; 2018 Jan; 66(1):170-178. PubMed ID: 29131306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.
    Hyde C; Peters J; Bond M; Rogers G; Hoyle M; Anderson R; Jeffreys M; Davis S; Thokala P; Moxham T
    Age Ageing; 2013 Jan; 42(1):14-20. PubMed ID: 23179169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis.
    Green C
    Pharmacoeconomics; 2007; 25(9):735-50. PubMed ID: 17803333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.